drug
Rybelsus
Marketedupdated 6mo agoby Novo Nordisk Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugOzempic121 co-mentions · 73 sources
- drugWegovy121 co-mentions · 73 sources
- drugWegovy Pill94 co-mentions · 72 sources
- tagApproval88 co-mentions · 44 sources
- drugsemaglutide72 co-mentions · 72 sources
- tagRecall29 co-mentions · 27 sources
- tagSmall Molecule17 co-mentions · 17 sources
- companyNovo Nordisk Inc11 co-mentions · 4 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Rybelsus
- phase3AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- phase1Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
- phase3A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- phase4Semaglutide vs Sitagliptin
- phase3A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase3A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
News(10)
- STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesityHow obesity medications may become the next big battleground over access to medicines in lower-income countries.stat · 10h ago
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 13h ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 3d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 5d ago
- Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorderHaving linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.biospace · 6d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 7d ago
- Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testThe Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…biospace · 7d ago
- Merck’s MASH hopeful efinopegdutide wins in mid-stage studyMerck & Co. revealed results from a mid-stage clinical trial showing its GLP-1 and glucagon receptor co-agonist efinopegdutide resolved cases of MASH compared with placebo without worsening liver f…fiercebiotech · 7d ago
- Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitorRezera—the new name for NodThera—is aiming for a $181 million IPO to take its NLRP3 inhibitor into phase 3 trials for a cardiovascular disease.fiercebiotech · 11d ago
- Novo, Lilly battle for oral GLP-1 dominance with data tit for tatNovo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.biospace · 12d ago
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that